Literature DB >> 29449725

Iatrogenic colorectal Kaposi's sarcoma complicating a refractory ulcerative colitis in a human immunodeficiency negative-virus patient.

L Chtourou1, L Ayedi2, H Rejab3, M Boudabous1, L Mnif1, A Grati1, T Boudaouara2, R Mzali3, A Amouri1, N Tahri1.   

Abstract

Kaposi sarcoma is an unusual tumor associated to a human herpes virus-8 infection involving the skin or internal organs. Iatrogenic Kaposi's sarcoma often occurs in patients receiving immunosuppressive therapy. So far, a few Kaposi's sarcoma cases have been reported in the literature associated with inflammatory bowel diseases. We report a 53-year-old male diagnosed with a severe refractory ulcerative colitis who was treated with corticosteroids and azathioprine. The patient underwent a colectomy after the failure of medical treatment. Histological examination of the colon showed findings suggestive of Kaposi's sarcoma. Immunohistochemistry for human herpes virus-8 was positive in the colonic lesions. Correspondence. © Copyright Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.

Entities:  

Keywords:  Corticosteroids; Human Herpes Virus-8; Iatrogenic; Immunosuppression; Kaposi’s Sarcoma; Ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 29449725

Source DB:  PubMed          Journal:  Pathologica        ISSN: 0031-2983


  2 in total

1.  Iatrogenic Kaposi sarcoma of the terminal ileum following short-term treatment with immunomodulators for Crohn disease: A case report.

Authors:  Elisa Stasi; Stefania De Santis; Elisabetta Cavalcanti; Raffaele Armentano
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 2.  Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature.

Authors:  Valerio Papa; Maria Cristina Giustiniani; Loris Riccardo Lopetuso; Alfredo Papa
Journal:  BMC Gastroenterol       Date:  2020-03-24       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.